LATAM MedTech Insights Podcast Por Ran Chen arte de portada

LATAM MedTech Insights

LATAM MedTech Insights

De: Ran Chen
Escúchala gratis

Welcome to LATAM MedTech Insights, your essential guide to the booming medical technology and digital health sector across Latin America. Each episode, we dissect the key trends, investment opportunities, and regulatory news shaping the industry. Join us for in-depth interviews with the innovators, investors, and policymakers driving the future of healthcare from Mexico to Brazil.Copyright 2026 Ran Chen Ciencia Ciencias Biológicas Economía
Episodios
  • Brazil's AI MedTech Crackdown: Pure Global on ANVISA's New Cybersecurity Demands

    Brazil's AI MedTech Crackdown: Pure Global on ANVISA's New Cybersecurity Demands
    Mar 27 2026
    Brazil's MedTech landscape is shifting. A quiet but powerful new technical note from ANVISA has just redefined the rules for AI-powered medical devices, creating immediate hurdles for global manufacturers. This update directly links cybersecurity and data privacy to the core of the device approval process, impacting all new and pending registrations. In this episode, we dissect the three critical areas of this clarification, from new clinical data expectations to the now-mandatory Software Bill of Materials (SBOM). We explore how ANVISA is tightening its alignment with Brazil's General Data Protection Law (LGPD) and what it means for your technical dossier. This is essential listening for any innovator looking to enter or expand within Latin America's largest market. Case Study Spotlight: Imagine your cutting-edge AI diagnostic software is deep into the ANVISA review process, and your launch in Brazil seems imminent. Suddenly, your application is stalled by a list of unexpected technical questions about cybersecurity monitoring and LGPD compliance, topics your initial submission only briefly touched upon. Your team must now scramble to produce new documentation that meets these unwritten rules, delaying your market entry by months and putting you behind competitors. What’s your next move. Key Takeaways: - What are the three most critical changes in ANVISA's new interpretation of AI SaMD regulations. - How does this technical note immediately affect your pending medical device submission in Brazil. - Why has a Software Bill of Materials (SBOM) suddenly become essential for approval. - Is your current cybersecurity plan robust enough to satisfy both ANVISA and Brazil's LGPD. - What specific documentation do you need to prepare now to avoid registration delays. - How can you transform this new regulatory challenge into a powerful competitive advantage. At Pure Global, we specialize in navigating these complex and evolving regulatory landscapes. Our team of local experts in Brazil, combined with advanced AI and data tools, provides end-to-end solutions to ensure your MedTech and IVD products achieve and maintain market access. From initial regulatory strategy and dossier submission to post-market surveillance, we streamline your path into over 30 global markets. Don't let unexpected regulatory shifts derail your expansion. Contact Pure Global at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.
    Más Menos
    2 m
  • Pure Global: Mexico's FDA Fast-Track - The COFEPRIS Secret Handshake for 510(k) Devices

    Pure Global: Mexico's FDA Fast-Track - The COFEPRIS Secret Handshake for 510(k) Devices
    Mar 26 2026
    Last week, Mexico's regulatory body, COFEPRIS, enhanced its partnership with the U.S. FDA, launching a new phase of its fast-track program for medical devices. This creates an accelerated approval pathway for devices already cleared in the United States, representing a landmark shift in the region's regulatory landscape. This episode dissects the massive opportunity this presents, which can cut market entry timelines from years down to just months. We explore which devices qualify, the detailed submission requirements, and what "regulatory reliance" truly means for your quality and post-market surveillance strategy. **Burning Questions for This Episode:** * Which specific device categories are eligible for the new COFEPRIS-FDA fast-track program? * What exact FDA documentation is now required for a streamlined submission to COFEPRIS? * How does this reliance pathway change the responsibilities of your Mexican Registration Holder? * What are the new, immediate post-market reporting obligations under this program? * Is this accelerated pathway a sign of a permanent shift in Mexican regulatory policy? * How can you leverage your existing 510(k) or PMA to maximize this opportunity? * What are the hidden compliance risks that could disqualify you from the program? At Pure Global, we specialize in navigating these complex regulatory shifts. We offer end-to-end solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline market access in over 30 countries, including Mexico. Whether you need to prepare a dossier for this new pathway or develop a broader LATAM strategy, our team is here to help. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.
    Más Menos
    2 m
  • Pure Global: Brazil's MedTech Compliance & ANVISA's New Hidden Hurdles.

    Pure Global: Brazil's MedTech Compliance & ANVISA's New Hidden Hurdles.
    Mar 25 2026
    Brazil's medical device market is undergoing a seismic shift. The national regulator, ANVISA, has just released RDC 848/2024, a sweeping new resolution that redefines the essential safety and performance requirements for all medical devices and IVDs. This isn't just a simple update; it's a new paradigm that demands a total lifecycle approach to compliance and introduces stringent new rules for high-tech areas like software and cybersecurity. This episode breaks down exactly what this means for manufacturers, especially those from outside Latin America. We reveal the hidden hurdles that can derail your product launch and lead to costly delays. For example, a US-based company with FDA clearance found its market entry plan blocked overnight, needing a complete overhaul of its technical dossier to meet Brazil's new, specific cybersecurity and clinical data requirements, delaying their launch by eight months. Key Takeaways: - How does ANVISA's RDC 848/2024 impact your current Brazil registration strategy? - Are your device's cybersecurity protocols robust enough for the new, explicit requirements? - What are the biggest compliance gaps this regulation creates for devices already approved in the EU or US? - Why is a 'total lifecycle' approach to risk management now mandatory for market access in Brazil? - How can you proactively update your technical dossier to prevent rejection under these new rules? - What specific clinical evidence is now required to prove performance claims to ANVISA? - Does this new regulation affect your post-market surveillance obligations? At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies to streamline global market access. We combine local expertise in over 30 markets, including Brazil, with advanced AI to navigate complex changes like RDC 848/2024, ensuring your path to market is efficient and successful. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.
    Más Menos
    3 m
Todavía no hay opiniones